SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

Stephen V. Faraone, Ph.D.

Speaker Affiliation
Stephen V. Faraone, Ph.D.
Departments of Psychiatry & of Neuroscience and Physiology
SUNY Upstate Medical University

: Quality Measures for ADHD Overview
Activity/Course #:
: Free
Release/Start Date:
: Dec 11 2018
Expiration Date:
: Dec 10 2020
: Psychiatry
Target Audience:
: Primary Care Providers
: ADHD Dissemination Webcast
Estimated Time To Complete CME Activity:
: 0.5 Hours
: 0.50 AMA PRA Category I Credit(s)
Hardware/Software Requirements:
In this webcast, Dr. Faraone discusses  the overview of best practices for treating and monitoring ADHD in adults.

This webcast was recorded live and is being used with the permission of the presenter.

Learning Objectives

At the conclusion of this activity, the learner will be able to:

  1. Explain the process of creating Quality Measures
  2. Explain the goals of disseminating Quality Measures
  3. Understand how Quality Measures apply to ADHD care
  4. Delineate stages of treatment in quality care for ADHD patients

How To Obtain Your CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Creditsô. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure is provided below.

In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, Genomind and Neurolifesciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Shire, Neurovance, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Childís Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is principal investigator of Dr. Faraone is supported by the K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway, the European Unionís Seventh Framework Programme for research; technological development and demonstration under grant agreement no 602805, the European Unionís Horizon 2020 research and innovation programme under grant agreement No 667302 and NIMH grants 5R01MH101519 and U01 MH109536-01.

Jonathan Marx, Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, CHCP, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an independent medical educational grant from Sunovion Pharmaceuticals Inc.